NERV – Minerva Neurosciences Inc.
Minerva Neurosciences, IncNERV
$6.07Name : Minerva Neurosciences, Inc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $262,675,616.00
EPSttm : -34.67
Minerva Neurosciences, Inc
$6.07
1.78%$0.11
NERV — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.57
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.46
EPS Last/This Y
1.29
EPS This/Next Y
0.12
Price
6.18
Target Price
7.25
Analyst Recom
3
Performance Q
55.67
Upside
-9,640.5%
Beta
-0.21
Ticker: NERV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | NERV | 6.9 | N/A | N/A | 0 |
| 2026-03-03 | NERV | 6.94 | N/A | N/A | 0 |
| 2026-03-04 | NERV | 6.74 | N/A | N/A | 0 |
| 2026-03-05 | NERV | 5.97 | N/A | N/A | 0 |
| 2026-03-06 | NERV | 6.05 | N/A | N/A | 0 |
| 2026-03-09 | NERV | 8.02 | N/A | N/A | 0 |
| 2026-03-10 | NERV | 7.89 | N/A | N/A | 0 |
| 2026-03-11 | NERV | 7.27 | N/A | N/A | 0 |
| 2026-03-12 | NERV | 7.69 | N/A | N/A | 0 |
| 2026-03-13 | NERV | 7.69 | N/A | N/A | 0 |
| 2026-03-17 | NERV | 7.9 | N/A | N/A | 0 |
| 2026-03-18 | NERV | 7.75 | N/A | N/A | 0 |
| 2026-03-19 | NERV | 8.07 | N/A | N/A | 0 |
| 2026-03-20 | NERV | 7.59 | N/A | N/A | 0 |
| 2026-03-23 | NERV | 6.42 | N/A | N/A | 0 |
| 2026-03-24 | NERV | 6.04 | N/A | N/A | 0 |
| 2026-03-25 | NERV | 6.09 | N/A | N/A | 0 |
| 2026-03-26 | NERV | 6.13 | N/A | N/A | 0 |
| 2026-03-27 | NERV | 6.16 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-02 | NERV | 6.90 | 80.4 | - | -1.40 |
| 2026-03-03 | NERV | 6.89 | 80.4 | - | -1.40 |
| 2026-03-04 | NERV | 6.78 | 80.4 | - | -1.40 |
| 2026-03-05 | NERV | 5.97 | 80.4 | - | -1.40 |
| 2026-03-06 | NERV | 6.05 | 80.4 | - | -1.40 |
| 2026-03-09 | NERV | 8.06 | 80.4 | - | -1.40 |
| 2026-03-10 | NERV | 7.93 | 80.4 | - | -1.40 |
| 2026-03-11 | NERV | 7.32 | 80.4 | - | -1.40 |
| 2026-03-12 | NERV | 7.66 | 80.4 | - | -1.40 |
| 2026-03-13 | NERV | 7.87 | 80.4 | - | -1.40 |
| 2026-03-17 | NERV | 7.89 | 72.0 | - | -0.54 |
| 2026-03-18 | NERV | 7.79 | 72.0 | - | -0.54 |
| 2026-03-19 | NERV | 8.05 | 72.0 | - | -0.54 |
| 2026-03-20 | NERV | 7.57 | 74.0 | - | -0.60 |
| 2026-03-23 | NERV | 6.49 | 74.0 | - | -0.60 |
| 2026-03-24 | NERV | 6.04 | 74.0 | - | -0.60 |
| 2026-03-25 | NERV | 6.09 | 74.0 | - | -0.60 |
| 2026-03-26 | NERV | 6.14 | 74.0 | - | -0.60 |
| 2026-03-27 | NERV | 6.18 | 74.0 | - | -0.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-02 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-03 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-04 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-05 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-06 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-09 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-10 | NERV | 0.00 | 32.61 | 1.21 |
| 2026-03-11 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-12 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-13 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-17 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-18 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-19 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-20 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-23 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-24 | NERV | 0.00 | 32.61 | 1.23 |
| 2026-03-25 | NERV | 0.00 | 32.61 | 1.57 |
| 2026-03-26 | NERV | 0.00 | 32.61 | 1.57 |
| 2026-03-27 | NERV | 0.00 | 32.61 | 1.57 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.64
Avg. EPS Est. Current Quarter
-0.13
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
Institutional Transactions
32.61
Beta
-0.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
27
Growth Score
19
Sentiment Score
11
Actual DrawDown %
78.2
Max Drawdown 5-Year %
-95.2
Target Price
7.25
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-26.8
Average EPS Est. Cur. Y
-0.6
EPS Next Y. (Est.)
-0.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.8
Return on Equity vs Sector %
181.1
Return on Equity vs Industry %
197.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.06
EBIT Estimation
◆
NERV
Healthcare
$6.18
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.6
Range 1M
34.9%
Sup Dist
5.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
61.1%
EPS NY
15%
52W%
45.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+17.3% upside
Upside
+17.3%
Quality
27
Minerva Neurosciences, IncSector: Healthcare
Industry: Biotechnology
Employees: 7
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
NERV
Latest News
—
Caricamento notizie per NERV…
stock quote shares NERV – Minerva Neurosciences Inc. Stock Price stock today
news today NERV – Minerva Neurosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NERV – Minerva Neurosciences Inc. yahoo finance google finance
stock history NERV – Minerva Neurosciences Inc. invest stock market
stock prices NERV premarket after hours
ticker NERV fair value insiders trading